biologic

Alphanate

Antihemophilic Factor/von Willebrand Factor Complex (Human)

Loss of exclusivityJune 2026projected — 12-year biologic exclusivity estimate
CompanyGrifols Biologicals LLC

Drug detail

Brand nameAlphanate
Active ingredientAntihemophilic Factor/von Willebrand Factor Complex (Human)
Strength2000IU
Dosage formFor Injection
RouteIntravenous
ModalityBiologic
FDA approvalJune 2014
Marketing statusRx

Source: FDA Purple Book, layered on the CliffBio company graph. Cliff dates are the projected — 12-year biologic exclusivity estimate; estimates are projections, not legal advice.

Alphanate patent cliff — loss of exclusivity June 2026 | CliffBio